Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis.

Cohan, Stanley L; Lucassen, Elisabeth B; Romba, Meghan C; Linch, Stefanie N

Cohan, Stanley L; Lucassen, Elisabeth B; Romba, Meghan C; Linch, Stefanie N.

Afiliação

Cohan SL; Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR 97225, USA. Stanley.Cohan@Providence.org.
Lucassen EB; Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR 97225, USA. elisabeth.lucassen@providence.org.
Romba MC; Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR 97225, USA. meghan.romba@providence.org.
Linch SN; Providence Health and Services, Regional Research Department, Portland, OR 97213, USA. stefanie.linch@providence.org.

Biomedicines ; 7(1)2019 Mar 11.

Article em En | MEDLINE | ID: mdl-30862055

Palavras-chave

CD25; DRESS; autoimmunity; daclizumab; drug reaction with eosinophilia systemic symptoms; innate immune system; interleukin-2; relapsing multiple sclerosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2019 Tipo de documento: Article